VABOMERE
Peakmeropenem-vaborbactam
NDAINTRAVENOUSPOWDERPriority Review
Approved
Aug 2017
Lifecycle
Peak
Competitive Pressure
0/100
Clinical Trials
3
Data completeness
5/8 — Partial
Priority Review
VABOMERE (meropenem-vaborbactam) is beta lactamase inhibitors [moa]. First approved in 2017.
Drug data last refreshed 2d ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
VABOMERE is a fixed-dose IV combination of meropenem (carbapenem beta-lactam) and vaborbactam (beta-lactamase inhibitor) designed to treat serious gram-negative infections resistant to standard carbapenems. It works by protecting meropenem from degradation by bacterial beta-lactamases, restoring efficacy against carbapenem-resistant organisms. The drug targets life-threatening hospital-acquired infections including bloodstream infections, ventilator-associated pneumonia, and hospital-acquired pneumonia.
$2MPart D
Peak13.0 years to LOELow commercial volume ($2M spend, 530 claims in 2023) suggests a niche specialist product with stable but modest market presence and likely small commercial team dedicated to infectious disease specialists.
Mechanism of Action
beta Lactamase Inhibitors
Pharmacologic Class:
beta Lactamase Inhibitor
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (3)
Dose-finding, Pharmacokinetics, and Safety of VABOMERE in Pediatric Subjects With Bacterial Infections
Started Jul 2016
39 enrolled
Bacterial Infections
Efficacy/Safety of Meropenem-Vaborbactam Compared to Piperacillin-Tazobactam in Adults With cUTI and AP
Started Nov 2014
550 enrolled
Urinary Tract Infection ComplicatedAcute Pyelonephritis
Efficacy, Safety, Tolerability of Vabomere Compared to Best Available Therapy in Treating Serious Infections in Adults
Started Jul 2014
77 enrolled
Urinary Tract Infection ComplicatedAcute PyelonephritisHospital Acquired Bacterial Pneumonia+3 more
Career Relevance
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.